A Randomised, Placebo-controlled, Double-blind, Incomplete Cross-over Design Trial to Evaluate the Effects of Liraglutide on Gastric Emptying, Energy Expenditure and Appetite, and to Evaluate Liraglutide Pharmacokinetics in Non-diabetic Obese Subjects.

Trial Profile

A Randomised, Placebo-controlled, Double-blind, Incomplete Cross-over Design Trial to Evaluate the Effects of Liraglutide on Gastric Emptying, Energy Expenditure and Appetite, and to Evaluate Liraglutide Pharmacokinetics in Non-diabetic Obese Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 31 Jul 2017

At a glance

  • Drugs Liraglutide (Primary)
  • Indications Obesity
  • Focus Pharmacodynamics
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 15 May 2013 Results presented at the 20th European Congress on Obestiy.
    • 05 Oct 2012 Results presented at the 48th Annual Meeting of the European Association for the Study of Diabetes.
    • 24 Sep 2012 Seconadary endpoints presented at the 2012 Annual Meeting of the North American Association for the Study of Obesity.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top